abiraterone,olaparib
astrazeneca,merck
['propel', 'gu ', 'msd', 'astrazeneca']
astrazeneca and msd present final results of key secondary overall survival endpoint from phase iii propel trial at asco gu cancers symposium 
Press- and earnings-releases in English and Swedish.